September 10, 2010

Countervail Corporation is awarded $346,000 for Phase 1 of Fast track SBIR Grant from the National Institutes of Health for Studies of Nerve Gas Antidote. Read More >>

August 2, 2007

Dr. Edson Albuquerque to present research data supporting use of Galantamine as a novel nerve-gas antidote countermeasure at Barda Industry Day. Read More >>

July 30, 2007

Countervail Signs Exclusive Nerve Gas antidote License with University of Maryland, Baltimore. Read More >>